Trial Profile
A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSONS DISEASE PATIENTS WITH MOTOR FLUCTUATIONS
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs Safinamide (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Acronyms EVEREST
- Sponsors Zambon SpA
- 15 Feb 2017 Status changed from recruiting to discontinued as confirmed from the investigator.
- 12 Jan 2016 Results published in Zambon media release.
- 01 Dec 2015 New trial record